Q3 Earnings Forecast for Evommune Issued By Leerink Partnrs

Evommune, Inc. (NYSE:EVMN) – Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Evommune in a research report issued on Monday, December 1st. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($1.00) for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Evommune’s Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.00) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.81) EPS, FY2028 earnings at ($3.78) EPS and FY2029 earnings at ($4.92) EPS.

A number of other analysts have also issued reports on the company. Leerink Partners assumed coverage on Evommune in a report on Monday. They issued an “outperform” rating and a $42.00 price target for the company. Cantor Fitzgerald started coverage on Evommune in a report on Monday. They issued an “overweight” rating for the company. Evercore ISI began coverage on Evommune in a report on Monday. They issued an “outperform” rating and a $40.00 target price for the company. Wall Street Zen upgraded Evommune to a “hold” rating in a research note on Thursday, November 20th. Finally, William Blair assumed coverage on Evommune in a report on Monday. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $39.33.

Evommune Stock Up 1.2%

Shares of EVMN stock opened at $21.16 on Wednesday. Evommune has a one year low of $16.70 and a one year high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.